Global Gastrointestinal Drugs Market: Overview

Gastro esophageal reflux disease (GERD), inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are types of gastrointestinal disease. Gastro esophageal reflux disease (GERD) is a chronic gastric illness that arises when acidic juices in the stomach come back up into the esophagus from stomach, this can leads to irritation of esophagus and causes symptoms like heartburn, gas, etc. Inflammatory bowel disease is a group of chronic inflammation of small and large intestine. Ulcerative Colitis and Crohn's disease are the two major types of inflammatory bowel disease. Irritable bowel syndrome (IBS) is a chronic condition that affects the colon (large intestine). Diarrhea, constipation, abdominal pain, cramping are the common symptoms of irritable bowel disease.

The market overview section of the report comprises qualitative analysis of the overall gastrointestinal drugs market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porters five force analysis and market attractiveness analysis. In addition, such as market opportunity analysis for the drug class, route of administration, drug class, distribution channel, and key industry developments has also been provided. Key industry developments include the major events occurred in past 4-5 years and are expected to occur during the forecast period which are likely to affect the market dynamics.

Global Gastrointestinal Drugs Market: Segmentation

The global gastrointestinal drugs market has been segmented on the basis of drug class, route of administration, drug class, distribution channel. On the basis of drug class the global gastrointestinal drugs market is segmented into acid neutralizers, antidiarrheal and laxatives, antiemetic and antinauseants, anti-inflammatory drugs, biologics and others including antispasmodic etc. The acid neutralizer segment is again segmented as antacids, H2 antagonists and Proton pump inhibitors. On the basis of route of administration, the global gastrointestinal drugs market has been segmented into three types such as, oral, parenteral and rectal. Based on disorder type, the global gastrointestinal drugs market is segmented into gastro esophageal reflux disease, inflammatory bowel
disease and Irritable bowel syndrome. On the basis of distribution channel, the global gastrointestinal drugs market is segmented as hospital pharmacies, retail pharmacies and online pharmacies.

The market for these drug class, route of administration, disorder type, and distribution channel has been extensively analyzed on the basis of factors such as usage pattern, sales revenue, and geographic presence and product developments. The market size and forecast in terms of revenue (US$ million), for each of these segments, and the sub-segments have been provided for the period 2014 to 2024, considering 2015 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2016 to 2024.

Geographically, the gastrointestinal drugs market has been classified into five segments, namely, North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size forecast for each region has been provided for the period 2014 to 2024, in terms of drug class, route of administration, disorder type, and distribution channel, along with the CAGR (%) for the forecast period 2016 to 2024.

**Global Gastrointestinal Drugs Market: Competitive Analysis**

The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global gastrointestinal drugs market, in terms of percentage share in 2016 (estimated) has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share.

The report concludes with the profiles of major players in the global gastrointestinal drugs market such as Takeda pharmaceutical, Valeant Pharmaceuticals International, Inc., Janssen Biotech, Inc., Bayer AG, Sanofi, AstraZeneca, Allergan Plc, GlaxoSmithKline, Abbott Laboratories, Boehringer Ingelheim GmbH and Allergan Plc., among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.

**The global gastrointestinal drugs market is segmented as follows:**

**By Drug Class**

- Acid Neutralizers
- Antacids
- H2 antagonists
- Proton pump inhibitors
- Antidiarrheal and Laxatives
- Antiemetic and Antinauseants
- Anti-inflammatory drugs
- Biologics
- Others (Antispasmodic etc.)

By Route of Administration

- Oral
- Parenteral
- Rectal

By Disorder Type

- Gastro Esophageal Reflux Disease
- Inflammatory Bowel Disease
- Irritable Bowel Syndrome

By Distribution Channel

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

By Region

- North America
- U.S.
- Canada
- Europe
- Germany
- France
U.K.
Italy
Russia
Spain
Rest of Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Southern Global
Middle East & Africa
GCC countries
South Africa
Rest of Middle East & Africa

Table Of Content

Notes:

Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology
3. Executive Summary: Global Gastrointestinal Drugs Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Gastrointestinal Drugs Market Overview

5. Market Dynamics
5.1. Drivers
5.1.1. Restraints
5.1.2. Opportunity
5.1.3. Trends
5.2. Porters Five Force Analysis
5.3. FDA Approved Biologics Products
5.4. Overview of Clinical Trials
5.5. Epidemiology of Gastrointestinal Disease: Global Scenario
5.6. Global prevalence of Inflammatory Bowel Disease in 2015

6. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Size (US$ Mn) Forecast By Drug Class
6.4.1. Acid Neutralizers
6.4.1.1. Antacids
6.4.1.2. H2 antagonists
6.4.1.3. Proton pump inhibitors
6.4.1.4. Helicobacter pylori eradication
6.4.2. Antidiarrheal and Laxatives
6.4.3. Antiemetic and Antinauseants
6.4.4. Anti-inflammatory drugs
6.4.5. Biologics
6.4.6. Others (Antispasmodic etc.)
6.5. Market Attractiveness By Drug Class

7. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends
7.4. Market Size (US$ Mn) Forecast By Route of Administration
   7.4.1. Oral
   7.4.2. Intravenous
   7.4.3. Rectal
7.5. Market Attractiveness By Route of Administration

8. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Disorder Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Key Trends
8.4. Market Size (US$ Mn) Forecast By Disorder Type
   8.4.1. Gastroesophageal Reflux Disease
   8.4.2. Inflammatory Bowel Disease
   8.4.3. Irritable Bowel Syndrome
8.5. Market Attractiveness By Disorder Type

9. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Key Trends
9.4. Market Size (US$ Mn) Forecast By Distribution Channel
   9.4.1. Hospital Pharmacies
   9.4.2. Retail Pharmacies
   9.4.3. Online Pharmacies
9.5. Market Attractiveness By Distribution Channel

10. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Policies and Regulations
10.3. Market Size (US$ Mn) Forecast By Region
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. Asia Pacific
10.3.5. Middle East and Africa
10.4. Market Attractiveness By Country/Region

11. North America Gastrointestinal Drugs Market Analysis and Forecast

11.1. Key Findings
11.2. Policies and Regulations
11.3. Key Trends
11.4. Market Value Forecast By Country
11.4.1. US
11.4.2. Canada
11.5. Market Size (US$ Mn) Forecast By Drug Class
11.5.1. Acid Neutralizers
11.5.1.1. Antacids
11.5.1.2. H2 antagonists
11.5.1.3. Proton pump inhibitors
11.5.1.4. Helicobacter pylori eradication
11.5.2. Antidiarrheal and Laxatives
11.5.3. Antiemetic and Antinauseants
11.5.4. Anti-inflammatory drugs
11.5.5. Biologics
11.5.6. Others (Antispasmodic etc.)
11.6. Market Size (US$ Mn) Forecast By Route of Administration
11.6.1. Oral
11.6.2. Intravenous
11.6.3. Rectal
11.7. Market Size (US$ Mn) Forecast By Disorder Type
11.7.1. Gastroesophageal Reflux Disease
11.7.2. Inflammatory Bowel Disease
11.7.3. Irritable Bowel Syndrome

11.8. Market Size (US$ Mn) Forecast By Distribution Channel
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Online Pharmacies

11.9. Market Attractiveness Analysis
11.9.1. By Country
11.9.2. By Drug Class
11.9.3. By Route of Administration
11.9.4. By Disorder Type
11.9.5. By Distribution Channel

12. Europe Gastrointestinal Drugs Market Analysis and Forecast
12.1. Key Findings
12.2. Policies and Regulations
12.3. Key Trends
12.4. Market Value Forecast By Country
12.4.1. Germany
12.4.2. France
12.4.3. U.K.
12.4.4. Italy
12.4.5. Russia
12.4.6. Spain
12.4.7. Rest of Europe
12.5. Market Size (US$ Mn) Forecast By Drug Class
12.5.1. Acid Neutralizers
12.5.1.1. Antacids
12.5.1.2. H2 antagonists
12.5.1.3. Proton pump inhibitors
12.5.1.4. Helicobacter pylori eradication
12.5.2. Antidiarrheal and Laxatives
12.5.3. Antiemetic and Antinauseants
12.5.4. Anti-inflammatory drugs
12.5.5. Biologics
12.5.6. Others (Antispasmodic etc.)

12.6. Market Size (US$ Mn) Forecast By Route of Administration

12.6.1. Oral
12.6.2. Intravenous
12.6.3. Rectal

12.7. Market Size (US$ Mn) Forecast By Disorder Type

12.7.1. Gastroesophageal Reflux Disease
12.7.2. Inflammatory Bowel Disease
12.7.3. Irritable Bowel Syndrome

12.8. Market Size (US$ Mn) Forecast By Distribution Channel

12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies

12.9. Market Attractiveness Analysis

12.9.1. By Country
12.9.2. By Drug Class
12.9.3. By Route of Administration
12.9.4. By Disorder Type
12.9.5. By Distribution Channel

13. Asia Pacific Gastrointestinal Drugs Market Analysis and Forecast

13.1. Key Findings
13.2. Policies and Regulations
13.3. Key Trends

13.4. Market Value Forecast By Country

13.4.1. China
13.4.2. Japan
13.4.3. India
13.4.4. Australia & New Zealand
13.4.5. India
13.4.6. Rest of Asia Pacific

13.5. Market Size (US$ Mn) Forecast By Drug Class

13.5.1. Acid Neutralizers
13.5.1.1. Antacids
13.5.1.2. H2 antagonists
13.5.1.3. Proton pump inhibitors
13.5.1.4. Helicobacter pylori eradication
13.5.2. Antidiarrheal and Laxatives
13.5.3. Antiemetic and Antinauseants
13.5.4. Anti-inflammatory drugs
13.5.5. Biologics
13.5.6. Others (Antispasmodic etc.)
13.6. Market Size (US$ Mn) Forecast By Route of Administration
13.6.1. Oral
13.6.2. Intravenous
13.6.3. Rectal
13.7. Market Size (US$ Mn) Forecast By Disorder Type
13.7.1. Gastroesophageal Reflux Disease
13.7.2. Inflammatory Bowel Disease
13.7.3. Irritable Bowel Syndrome
13.8. Market Size (US$ Mn) Forecast By Distribution Channel
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Market Attractiveness Analysis
13.9.1. By Country
13.9.2. By Drug Class
13.9.3. By Route of Administration
13.9.4. By Disorder Type
13.9.5. By Distribution Channel

14. Latin America Gastrointestinal Drugs Market Analysis and Forecast
14.1. Key Findings
14.2. Policies and Regulations
14.3. Key Trends
14.4. Market Value Forecast By Country
14.4.1. Brazil
14.4.2. Mexico
14.4.3. Rest of Latin America
14.5. Market Size (US$ Mn) Forecast By Drug Class
14.5.1. Acid Neutralizers
14.5.1.1. Antacids
14.5.1.2. H2 antagonists
14.5.1.3. Proton pump inhibitors
14.5.1.4. Helicobacter pylori eradication
14.5.2. Antidiarrheal and Laxatives
14.5.3. Antiemetic and Antinauseants
14.5.4. Anti-inflammatory drugs
14.5.5. Biologics
14.5.6. Others (Antispasmodic etc.)
14.6. Market Size (US$ Mn) Forecast By Route of Administration
14.6.1. Oral
14.6.2. Intravenous
14.6.3. Rectal
14.7. Market Size (US$ Mn) Forecast By Disorder Type
14.7.1. Gastroesophageal Reflux Disease
14.7.2. Inflammatory Bowel Disease
14.7.3. Irritable Bowel Syndrome
14.8. Market Size (US$ Mn) Forecast By Distribution Channel
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Market Attractiveness Analysis
14.9.1. By Country
14.9.2. By Drug Class
14.9.3. By Route of Administration
14.9.4. By Disorder Type
14.9.5. By Distribution Channel

15. Middle East & Africa Gastrointestinal Drugs Market Analysis and Forecast
15.1. Key Findings
15.2. Policies and Regulations
15.3. Key Trends

15.4. Market Value Forecast By Country
15.4.1. GCC countries
15.4.2. South Africa
15.4.3. Rest of Middle East & Africa

15.5. Market Size (US$ Mn) Forecast By Drug Class
15.5.1. Acid Neutralizers
15.5.1.1. Antacids
15.5.1.2. H2 antagonists
15.5.1.3. Proton pump inhibitors
15.5.1.4. Helicobacter pylori eradication
15.5.2. Antidiarrheal and Laxatives
15.5.3. Antiemetic and Antinauseants
15.5.4. Anti-inflammatory drugs
15.5.5. Biologics
15.5.6. Others (Antispasmodic etc.)

15.6. Market Size (US$ Mn) Forecast By Route of Administration
15.6.1. Oral
15.6.2. Intravenous
15.6.3. Rectal

15.7. Market Size (US$ Mn) Forecast By Disorder Type
15.7.1. Gastroesophageal Reflux Disease
15.7.2. Inflammatory Bowel Disease
15.7.3. Irritable Bowel Syndrome

15.8. Market Size (US$ Mn) Forecast By Distribution Channel
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies

15.9. Market Attractiveness Analysis
15.9.1. By Country
15.9.2. By Drug Class
15.9.3. By Route of Administration
15.9.4. By Disorder Type
15.9.5. By Distribution Channel
16. Competition Landscape
16.1. Market Player
16.2. Company Share Analysis (2016)
16.3. Company Profiles
16.3.1. Abbott Laboratories
16.3.1.1. Overview
16.3.1.2. Financials
16.3.1.3. Recent Developments
16.3.1.4. Strategy
16.3.2. Allergan Plc
16.3.2.1. Overview
16.3.2.2. Financials
16.3.2.3. Recent Developments
16.3.2.4. Strategy
16.3.3. AstraZeneca
16.3.3.1. Overview
16.3.3.2. Financials
16.3.3.3. Recent Developments
16.3.3.4. Strategy
16.3.4. Bayer AG
16.3.4.1. Overview
16.3.4.2. Financials
16.3.4.3. Recent Developments
16.3.4.4. Strategy
16.3.5. Boehringer Ingelheim GmbH
16.3.5.1. Overview
16.3.5.2. Financials
16.3.5.3. Recent Developments
16.3.5.4. Strategy
16.3.6. GlaxoSmithKline plc
16.3.6.1. Overview
16.3.6.2. Financials
16.3.6.3. Recent Developments
16.3.6.4. Strategy
16.3.7. Janssen Biotech, Inc.
16.3.7.1. Overview
16.3.7.2. Financials
16.3.7.3. Recent Developments
16.3.7.4. Strategy
16.3.8. Sanofi
16.3.8.1. Overview
16.3.8.2. Financials
16.3.8.3. Recent Developments
16.3.8.4. Strategy
16.3.9. Takeda Pharmaceutical
16.3.9.1. Overview
16.3.9.2. Financials
16.3.9.3. Recent Developments
16.3.9.4. Strategy
16.3.10. Valeant Pharmaceuticals, Inc.
16.3.10.1. Overview
16.3.10.2. Financials
16.3.10.3. Recent Developments
16.3.10.4. Strategy

Table 01: Biologics Products, Manufacturers & Trade Names
Table 02: Biologics Products, Manufacturers & Trade Names
Table 03: Overview of major clinical trials for Inflammatory Bowel Disease
Table 04: Overview of major clinical trials for Inflammatory Bowel Disease
Table 05: Overview of major clinical trials for Inflammatory Bowel Disease
Table 06: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014-2024
Table 07: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizer (Drug Class), 2014-2024
Table 08: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014-2024
Table 09: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014-2024
Table 10: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014-2024
Table 11: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Region, 2014-2024
Table 12: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014-2024
Table 13: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014-2024
Table 14: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class), 2014-2024
Table 15: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014-2024
Table 16: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014-2024
Table 17: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014-2024
Table 18: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014-2024
Table 19: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014-2024
Table 20: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class), 2014-2024
Table 21: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014-2024
Table 22: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014-2024
Table 23: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014-2024
Table 24: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014-2024
Table 25: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014-2024
Table 26: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class), 2014-2024
Table 27: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014-2024
Table 28: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014-2024
Table 29: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014-2024
Table 30: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014-2024
Table 31: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014-2024
Table 32: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class), 2014-2024
Table 33: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014-2024
Table 34: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014-2024
Table 35: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014-2024
Table 36: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014-2024
Table 37: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014-2024
Table 38: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers, 20142024
Table 39: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 20142024
Table 40: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 20142024
Table 41: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 20142024

Figure 01: Market Value Share, by Drug Class (2015)
Figure 02: Market Value Share, by Route of Administration (2015)
Figure 03: Market Value Share, by Disorder Type (2015)
Figure 04: Market Value Share, by Distribution Channel (2015)
Figure 05: Market Value Share, by Region (2015)
Figure 06: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, 20142024
Figure 07: Global Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 08: Global Acid Neutralizers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 20142024
Figure 09: Global Antidiarrheal and Laxatives Market Revenue (US$ Mn) and Y-o-Y Growth (%), 20142024
Figure 10: Global Antiemetic and Antinauseants Market Revenue (US$ Mn) and Y-o-Y Growth (%), 20142024
Figure 11: Global Anti-inflammatory drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 20142024
Figure 12: Global Biologics Market Revenue (US$ Mn) and
Figure 13: Global Others (Antispasmodic etc.) Market Revenue (US$ Mn) and Y-o-Y Growth (%), 20142024
Figure 14: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class
Figure 15: Global Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 16: Global Oral Market Revenue (US$ Mn) and Y-o-Y Growth (%), 20142024
Figure 17: Global Parenteral Market Revenue (US$ Mn) and Y-o-Y Growth (%), 20142024
Figure 18: Global Rectal Market Revenue (US$ Mn) and Y-o-Y Growth (%), 20142024
Figure 19: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 20162024
Figure 20: Global Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 21: Global Gastroesophageal Reflux Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), 20142024
Figure 22: Global Inflammatory Bowel Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), 20142024
Figure 23: Global Irritable Bowel Syndrome Market Revenue (US$ Mn) and Y-o-Y Growth (%), 20142024
Figure 24: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Disorder Type, 20162024
Figure 80: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 81: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 82: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 83: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 20162024
Figure 84: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 20162024
Figure 85: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 20162024
Figure 86: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 20162024
Figure 87: Global Gastrointestinal Drugs Market Share Analysis, by Company, 2016 (Estimated)